biotech
biotech Articles
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Published:
Last Updated:
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Published:
Last Updated:
Medivation, Inc. (NASDAQ: MDVN) was not having a great day on Wednesday. Its shares were seen down 5% or so at $33.10 shortly before the close. News was out on Tuesday signaling that the Journal of...
Published:
Last Updated:
Regeneron Pharmaceuticals seems to have held up rather well against an analyst downgrade on Wednesday.
Published:
Last Updated:
Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.
Published:
Last Updated:
Relypsa rose early in Monday’s session as the result of positive results from its Phase 1 in vivo studies evaluating the interactions between Veltassa (patiromer) and other drugs.
Published:
Last Updated:
Editas Medicine expects to price its nearly 6 million shares in the range of $16 to $18 per share in an initial public offering valued up to more than $122 million.
Published:
Last Updated:
Affimed shares rose on Monday following the announcement of a collaboration in immuno-oncology with biotech giant Merck.
Published:
Last Updated:
OncoMed Pharmaceuticals saw its stock sink early Monday morning following an update from its Phase 2 Alpine study.
Published:
Last Updated:
Merus has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
Alkermes absolutely tanked early Thursday morning on less than favorable preliminary top-line results from the first two of three Phase 3 efficacy studies for ALKS 5461.
Published:
Last Updated:
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Published:
Last Updated:
Despite facing setbacks recently, Zafgen pushed ahead and led the bulls early on Wednesday on news of positive results.
Published:
Last Updated:
AveXis has filed with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO).
Published:
Last Updated: